Is this you? Create Your Porfile
Avatar

S. Wanaski

Marathon Oil

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where S. Wanaski is active.

Explore More

Publication

Featured researches published by S. Wanaski.

Neuromuscular Disorders | 2016

Integrated prospective results from the deflazacort clinical program suggest less severe psychiatric adverse events with deflazacort versus prednisone in Duchenne muscular dystrophy

J. Dubow; P. Sazani; T. Cunniff; S. Wanaski; James Meyer

Neuromuscular Disorders | 2016

A comparison of the effects of deflazacort and prednisone versus placebo on timed functional tests in boys with Duchenne muscular dystrophy

James Meyer; J. Dubow; T. Cunniff; S. Wanaski

Neuromuscular Disorders | 2016

Glucocorticoids deflazacort and prednisone show muscle strength effects versus placebo in boys with Duchenne muscular dystrophy ages 5–7

P. Sazani; T. Cunniff; S. Wanaski; J. Dubow; James Meyer

Neuromuscular Disorders | 2016

Potential mechanisms for prolonged loss of ambulation with deflazacort in Duchenne muscular dystrophy – Tolerability profile and effects on growth

James Meyer; T. Cunniff; S. Wanaski; J. Dubow

Neuromuscular Disorders | 2016

Effect of deflazacort and prednisone versus placebo on muscle strength in boys with Duchenne muscular dystrophy who have lost ambulation: Results from the deflazacort clinical trial program

T. Cunniff; S. Wanaski; J. Dubow; James Meyer

Neuromuscular Disorders | 2016

Effect of deflazacort and prednisone on muscle enzymes in the treatment of Duchenne muscular dystrophy

J. Dubow; T. Cunniff; S. Wanaski; James Meyer

Neuromuscular Disorders | 2016

Effect of deflazacort and prednisone versus placebo on pulmonary function in boys with Duchenne muscular dystrophy who have lost ambulation

J. Dubow; T. Cunniff; S. Wanaski; James Meyer

Neuromuscular Disorders | 2016

Pharmacokinetics of 21-desacetyldeflazacort and the safety of deflazacort after oral administration to children and adolescents with Duchenne muscular dystrophy

S. Wanaski; P. Shieh; Nancy L. Kuntz; Emma Ciafaloni; Russell J. Butterfield; S. Brantley; L. Grasfeder; J. Dubow; B. Beers; E. Kernbauer; C. Wells; T. Cunniff; Robert C. Griggs

Neuromuscular Disorders | 2016

Relative bioavailability of 21-desacetyldeflazacort after oral administration of various deflazacort formulations and dosing conditions in healthy volunteer subjects

S. Wanaski; S. Brantley; L. Grasfeder; J. Dubow; B. Beers; E. Kernbauer; C. Wells; T. Cunniff

Neurology | 2016

Potential Mechanisms for Prolonged Loss of Ambulation with Deflazacort in Duchenne Muscular Dystrophy - Tolerability Profile and Effects on Growth (P5.059)

T. Cunniff; S. Wanaski; J. Dubow; James Meyer

Explore More

Collaboration

Dive into the S. Wanaski's collaboration.

Top Co-Authors
Avatar

J. Dubow

Marathon Oil

View shared research outputs
Top Co-Authors
Avatar

T. Cunniff

Marathon Oil

View shared research outputs
Top Co-Authors
Avatar

James Meyer

Marathon Oil

View shared research outputs
Top Co-Authors
Avatar

B. Beers

Marathon Oil

View shared research outputs
Top Co-Authors
Avatar

C. Wells

Marathon Oil

View shared research outputs
Top Co-Authors
Avatar

E. Kernbauer

Marathon Oil

View shared research outputs
Top Co-Authors
Avatar

P. Sazani

Marathon Oil

View shared research outputs
Top Co-Authors
Avatar

L. Grasfeder

Durham University

View shared research outputs
Top Co-Authors
Avatar

S. Brantley

Durham University

View shared research outputs
Top Co-Authors
Avatar

Elise M. Lewis

Charles River Laboratories

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge